scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10067-006-0356-5 |
P698 | PubMed publication ID | 16865310 |
P2093 | author name string | D Patakas | |
P Argyropoulou | |||
V Bagalas | |||
I Kioumis | |||
P2860 | cites work | Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years | Q38905579 |
Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab | Q40489366 | ||
Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy | Q40598694 | ||
Visceral leishmaniasis and HIV-1 co-infection in southern France | Q40687984 | ||
Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies | Q40833417 | ||
Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis | Q44494520 | ||
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism | Q67267340 | ||
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis | Q71160284 | ||
Granulomatous infections due to tumor necrosis factor blockade: correction | Q80867344 | ||
Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs | Q95810127 | ||
P433 | issue | 8 | |
P921 | main subject | rheumatoid arthritis | Q187255 |
visceral leishmaniasis | Q2046113 | ||
P304 | page(s) | 1344-1345 | |
P577 | publication date | 2006-07-25 | |
P1433 | published in | Clinical Rheumatology | Q15754927 |
P1476 | title | Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept | |
P478 | volume | 26 |
Q56771969 | Q56771969 |
Q61313261 | An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced byLeishmania major infection |
Q93011826 | Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression |
Q37306365 | Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe |
Q34665258 | Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model |
Q35219247 | New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. |
Q40627316 | Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-γ production by spleen cells from human visceral leishmaniasis patients |
Q40436057 | Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? |
Q39529489 | Visceral leishmaniasis in immunosuppressed Caucasian patient |